Table 1.

Distribution of included patients and their clinically assigned AIFELL scores.

Consecutive patients with suspected COVID-19 admitted via the ER from March through mid-April 2020 (n = 122; 72 males, 50 females)
Nasopharyngeal qPCR result	SARS-CoV-2 positive (n = 70, age 60.6 years ± 14.2)			SARS-CoV-2 negative (n = 52, 57.9 years ± 17.9)
Components of the AIFELL score:Altered smell or taste (yes/no), Inflammation (CRP ≥ 30 mg/L), Infiltrates (yes/no), Fever (≥ 38° C), Elevated LDH (>400 U/L), Lymphocytopenia (absolute count < 1.45 G/L)
Diagnosis	COVID-19 Stage I (n = 10)	COVID-19 Stage IIa (n = 31)	COVID-19 Stage IIb (n = 29)	Other respiratory problems like exacerbated COPD, bronchial asthma, bacterial pneumonia, aspiration pneumonitis, other viral infections (influenza, metapneumovirus), cardiac failure
Mean AIFELL score	1.8 ± 0.8	4.6 ± 0.8		2.2 ± 1.1
	4.19 ± 1.28
Total number n AIFELL positive (4–6 points)	0	29 (93.5%)	29 (100%)	5 (9.6%)
Total number n AIFELL negative (0 – 3 points)	10 (100%)	2 (6.5%)	0	47 (90.4%)

Legend: Results given as mean ± SD unless indicated otherwise. Stage III patients with progressive systemic inflammation were usually admitted directly to ICU from normal ward or other hospitals in our setting, not through the ER. Therefore, they are not mentioned in this table. SD, standard deviation.